




### **Networking Support Scheme**

# The anti-IgLON5 disease: Challenges in diagnosis, treatment and pathogenesis of the disease

#### General information

**Dates:** 24-25<sup>th</sup> of February 2022 **Workshop Venue:** Auditorium Esteve. Center Esther Koplowitz building. Carrer del Rosselló, 153, 08036 Barcelona.



### PRELIMINARY PROGRAM

## Day 1: CLINICAL AND PATHOLOGICAL ASPECTS OF ANTI-IgLON5 DISEASE

#### 9.00-9.40 Opening of the meeting. Introduction

Chairperson: Francesc Graus 9.00-9.15 Welcome. Francesc Graus. Anti-IgLON5 disease identification and their relevance as an autoimmune and neurodegenerative condition 9.15-9.25 Carles Gaig. From a sleep disorder to a novel neurological disease. 9.25-9.35 Lidia Sabater. From a neuronal antibody to a novel neurological disease 9.35-9.40 Summary. Francesc Graus. Key clinical and physio-pathological features of anti-IgLON5 disease and unsolved issues.



## 9.40-10.35 Clinical aspects of the anti-IgLON5 disease. Part 1: clinical features at presentation and challenges of the diagnostic.

Chairperson: Joan Santamaria

9.40-9.50 Amaia Muñoz. Sleep and bulbar manifestations

9.50-10.00 Anna Heidbreder. Movement disorders and cognitive dysfunction

10.00-10.30 Round table and audience discussion.

10.30-10.35 Joan Santamaria. Concluding remarks. Future working plans

#### Coffee break. 10.35-11.00

## 11.00-12.05 Clinical aspects of the anti-IgLON5 disease. Part 2: clinical features at evolution, and response to treatment.

Chairperson: Josep Dalmau

11.00-11.10 Carles Gaig. The natural history of anti-IgLON5 disease

11.10-11.20 Ilya Ayzenberg. Registry data from GENERATE

11.20-11.30 Marteen Titulaer. Treatment approaches. Paving the way for clinical trials.

11.30-12.00 Round table and audience discussion.

12.00-12.05 Josep Dalmau. Concluding remarks. Future working plans

#### 12.05-13.00 Neuropathological studies and diagnostic criteria.

Chairperson: Romana Hoeftberger

12.05-12.15 Romana Hoeftberger.

12.15-12.25 Ellen Gelpí.

12.25-12.55 Round table and audience discussion.

12.55-13.00 Romana Hoeftberger. Concluding remarks. Future working plan

#### 13.00-15.00 Lunch

#### 15.00-15.50 Neuroimaging

Chairperson: Jan Lewerenz
15.00-15.10 Carsten Finke. Brain magnetic resonance imaging in IgLON5.
15.10-15.20 Thilo van Eimeren. PET Tau imaging in IgLON5
15.20-15.55 Round table and audience discussion.
15.55-15.50 Jan Lewerenz. Concluding remarks. Future working plan.

#### 15.50-17.10 Biomarkers (neurodegenerative/autoimmune)

Chairperson: Frank Leypoldt 15.50-16.05 Frank Leypoldt. Neurodegenerative biomarkers in serum and CSF (Neurofilament light chain and beyond).

16.05-16.15 Daniela Esser. Neuroinflammatory markers in serum and CSF.

16.15-16.25 Inga Koneczny. IgG subtypes and clinical correlations.

16.25-17.00 Round table and audience discussion.

17.00-17.10 Frank Leypoldt Concluding remarks. Future working plan

#### Dinner. 20.00-21.30

#### Day 2: THE PATHOGENESIS OF THE ANTI-IGLON5 DISEASE



# 9.00-10.00 Genetic and immunological aspects of the anti-IgLON5 disease: HLA and beyond.

Chairperson: Emmanuel Mignot
9.00-9.10 Selina Yogeshwar. HLA association and its role in anti-IgLON5 disease
9.10-9.20 Gregor Kuhlenbäuer. GWAS data and IgG-ab subtypes
9.20-9.55 Round table and audience discussion.
09.55-10.00 Emmanuel Mignot. Concluding remarks. Future working plan

#### 10.00-11.00 From antibodies to tau phosphorylation

Chairperson: Lidia Sabater 10.00-10.10 Morteen Blaabjerg 10.10-10.20 Jon Landa 10.20-10.55 Round table and audience discussion 10.55-11.00 Lidia Sabater. Concluding remarks. Future working plan

Coffe break. 11.00-11.30

## 11.30-12.30 Link between Neuroinflammation and Neurodegeneration: Learning from other neurodegenerative diseases?:

Chairperson: Raquel Sánchez del Valle.

11.30-11.40.Antonio Boza. Microglia activation and Neuroinflammation in Neurodegenerative diseases.

11.40-11.50. Harro Seelaar. Neuroinflammatory and neurodegeneration pathways in tauopathies

11.50-12.20 Round table and audience discussion

12.20-12.25 Raquel Sánchez del Valle. Concluding remarks. Future working plan

### **12.25-12.40 The consortium collaboration agreement. Concluding remarks.** Carles Gaig/Lidia Sabater

